Pfizer's COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring, the company announced Tuesday.
A vial of the Pfizer COVID-19 vaccine for children 6 months through 4 years old is seen June 21, 2022, at Montefiore Medical Group in the Bronx borough of New York. New data from Pfizer and BioNTech show their tot-sized COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring. Vaccinations for babies, toddlers and preschoolers opened in the U.S. in June after months of delay.
Pfizer’s COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring, the company announced Tuesday. Health authorities authorized tot-sized vaccine doses made by Pfizer and its partner BioNTech based on a study showing they were safe and produced high levels of virus-fighting antibodies. But there was only preliminary data on how that translated into effectiveness against symptomatic COVID-19.